Yesterday, Sept. 14, 2015, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $45.99 to $17,514,351.66.

Highlighted Stocks Traded by Insiders:

Memorial Resource Development (MRD) - FREE Research Report

Hebert William, who is Shareholder at Memorial Resource Development, sold 5,000 shares at $20.10 on Sept. 14, 2015. Following this transaction, the Shareholder owned 284,912 shares meaning that the stake was reduced by 1.72% with the 5,000-share transaction.

The shares most recently traded at $19.18, down $0.92, or 4.8% since the insider transaction. Historical insider transactions for Memorial Resource Development go as follows:

  • 4-Week # shares sold: 419,920
  • 12-Week # shares sold: 989,920
  • 24-Week # shares bought: 8,127
  • 24-Week # shares sold: 2.6 million

The average volume for Memorial Resource Development has been 1.8 million shares per day over the past 30 days. Memorial Resource Development has a market cap of $3.7 billion and is part of the basic materials sector and energy industry. Shares are up 6.05% year-to-date as of the close of trading on Monday.

Memorial Resource Development Corp., an independent natural gas and oil company, focuses on the acquisition, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana. The company has a P/E ratio of 18.8. Currently, there are 9 analysts who rate Memorial Resource Development a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MRD - FREE

TheStreet Quant Ratings rates Memorial Resource Development as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full Memorial Resource Development Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RenaissanceRe Holdings (RNR) - FREE Research Report

Curtis Ross, who is SVP,Chief Underwriting Officer at RenaissanceRe Holdings, sold 5,000 shares at $105.00 on Sept. 14, 2015. Following this transaction, the SVP,Chief Underwriting Officer owned 94,892 shares meaning that the stake was reduced by 5.01% with the 5,000-share transaction.

The shares most recently traded at $105.32, up $0.32, or 0.3% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 15,127
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 24,793

The average volume for RenaissanceRe Holdings has been 349,200 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $4.8 billion and is part of the financial sector and insurance industry. Shares are up 8.17% year-to-date as of the close of trading on Monday.

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company operates in three segments: Catastrophe Reinsurance, Specialty Reinsurance, and Lloyd's. The stock currently has a dividend yield of 1.14%. The company has a P/E ratio of 9.0. Currently, there are 3 analysts who rate RenaissanceRe Holdings a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNR - FREE

TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pacira Pharmaceuticals (PCRX) - FREE Research Report

Scibetta James S, who is SVP, Chief Financial Officer at Pacira Pharmaceuticals, bought 5,000 shares at $61.37 on Sept. 14, 2015. Following this transaction, the SVP, Chief Financial Officer owned 10,504 shares meaning that the stake was boosted by 90.84% with the 5,000-share transaction.

The shares most recently traded at $65.36, up $3.99, or 6.1% since the insider transaction. Historical insider transactions for Pacira Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 22,746

The average volume for Pacira Pharmaceuticals has been 687,100 shares per day over the past 30 days. Pacira Pharmaceuticals has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are down 28.19% year-to-date as of the close of trading on Monday.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has a P/E ratio of 523.0. Currently, there are 6 analysts who rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCRX - FREE

TheStreet Quant Ratings rates Pacira Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and premium valuation. Get the full Pacira Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.